检索结果-南通市图书馆

Prospect of combination of anti-pd-1/pd-l1 therapy and other therapeutics for treatment of lung cancer

中国药理学与毒理学杂志 2019年第10期 888-888页

作者： WANG lu-yao YAO Rui-xue XU Qian-qian lIU Jia Department of Pharmacology School of Pharmacy Qingdao University

lung cancer is the leading cause of cancer death worldwide, mainly because it has no obvious symptoms at the early stage and it is usually diagnosed at the advanced stage. Surgery and chemotherapy are the main common treatment options for lung cancer patients. During the past 25 years, great progress has been made in the treatment of lung cancer. Novel materials such as nanoparticles have shown therapeutic potential for lung cancer as they can selectively enter tumor cells due to their small size and surface modifiability. However,the prognosis of patients with lung cancer is still unsatisfactory. Targeted immunotherapy has shown potential for the treatment of lung cancer. The anti-tumor immunotherapy has been widely concerned as immune escape plays an important role in the occurrence and development of tumors. In particular, agents targeting pd-1/pd-l1 have been widely studied and some anti-pd-1/pd-l1 agents have been approved for the treatment of lung cancer by FDA since they have shown significant anti-tumor activity in lung cancer patients. Nevertheless, not all patients response to this therapy and the immune-related adverse events have emerged. The immune-related adverse events mainly involve the gut, skin, endocrine glands, liver,lung and other tissues. With the development of this field, combination therapy has been regarded as a promising strategy to improve the safety and efficacy of antipd-1/pd-l1 therapy. Studies have shown that the radiotherapy, chemotherapy, oncolytic virus, antiangiogenic agents and indoleamine 2,3-dioxygenase(IDO) inhibitors may improve the efficacy and reduce the incidence of adverse events of anti-pd-1/pd-l1 therapy. Radiotherapy can not only kill tumor cells, but also stimulate the immune system by releasing tumor antigens. Chemotherapy may induce the tumor-specific adaptive immune *** virotherapy, which is a form of immunotherapy,can kill tumors directly and induce the host immune response to tumour cells. Angiogen

关键词： lung cancer anti-pd-1/pd-l1 therapy combination immunotherapy

来源：

同方期刊数据库评论

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

The role of intestinal flora on tumorigenesis,progression,and the efficacy of pd-1/pd-l1 antibodies in colorectal cancer

引用

Cancer Biology & Medicine 2024年第1期21卷 65-82页

作者： Sen Wang Benling Xu Yangyang Zhang Guangyu Chen Peng Zhao Quanli Gao long Yuan Department of Gastrointestinal Surgery Affiliated Cancer Hospital of Zhengzhou UniversityZhengzhou 450003China Department of Immunotherapy Affiliated Cancer Hospital of Zhengzhou UniversityZhengzhou 450003China

Intestinal flora affects the maturation of the host immune system,serves as a biomarker and efficacy predictor in the immunotherapy of several cancers,and has an important role in the development of colorectal cancer(CRC).anti-pd-1/pd-l1 antibodies have shown satisfactory results in MSI-H/d MMR CRC but performed poorly in patients with MSS/p MMR *** recent years an increasing number of studies have shown that intestinal flora has an important impact on anti-pd-1/pd-l1 antibody efficacy in CRC *** and clinical evidence have suggested that anti-pd-1/pd-l1 antibody efficacy can be improved by altering the composition of the intestinal flora in ***,we summarize the studies related to the influence of intestinal flora on anti-pd-1/pd-l1 antibody efficacy in CRC and discuss the potential underlying mechanism(s).We have focused on the impact of the intestinal flora on the efficacy and safety of anti-pd-1/pd-l1 antibodies in CRC and how to better utilize the intestinal flora as an adjuvant to improve the efficacy of anti-pd-1/pd-l1 *** addition,we have provided a basis for the potential of the intestinal flora as a new treatment modality and indicator for determining patient prognosis.

关键词： Intestinal flora anti-pd-1/pd-l1 therapy colorectal cancer immune checkpoint inhibitor CD8~+T cell

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：